Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05429268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Study acronym: firmMIND
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Apr 1, 2026 to Mar 30, 2026v33
  2. 2 versions Re-verified since Jul 3, 2025, no change to tracked fieldsv31-v32
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 81 to confirmed 82 · Primary completion date: Dec 24, 2025 to Apr 1, 2026 · Completion date: Dec 24, 2026 to Apr 1, 2027 · 1 morev30 Show 4 more changesShow less
    • Enrollment target: estimated 81 to confirmed 82
    • Primary completion date: Dec 24, 2025 to Apr 1, 2026
    • Completion date: Dec 24, 2026 to Apr 1, 2027
    • Site details revised at 61 of 61 sites
  4. Site details revised at 1 of 61 sitesv29
  5. Site details revised at 1 of 61 sitesv28
Show 26 earlier versionsHide 26 earlier versions
  1. Site details revised at 3 of 61 sitesv27
  2. Site details revised at 1 of 61 sitesv26
  3. Site details revised at 1 of 61 sitesv25
  4. Site details revised at 1 of 61 sitesv24
  5. Site details revised at 1 of 61 sitesv23
  6. Site details revised at 1 of 61 sitesv22
  7. Site details revised at 1 of 61 sitesv21
  8. Study sites revised (61)v20 See this version in full on ClinicalTrials.gov ↗
  9. Study sites revised (61)v19 See this version in full on ClinicalTrials.gov ↗
  10. Site details revised at 1 of 61 sitesv18
  11. Study sites: 60 to 61v17
  12. Site details revised at 1 of 60 sitesv16
  13. Site details revised at 1 of 60 sitesv15
  14. Site details revised at 1 of 60 sitesv14
  15. Site details revised at 1 of 60 sitesv13
  16. Study sites revised (60)v12 See this version in full on ClinicalTrials.gov ↗
  17. Site details revised at 2 of 60 sitesv11
  18. Site details revised at 1 of 60 sitesv10
  19. Site details revised at 1 of 60 sitesv9
  20. Site details revised at 2 of 60 sitesv8
  21. Study sites: 58 to 60v7
  22. Primary completion date: Dec 24, 2026 to Dec 24, 2025 Start date changed from estimate of Nov 16, 2022 to Dec 23, 2022 · Site details revised at 10 of 58 sitesv6 Show 2 more changesShow less
    • Start date changed from estimate of Nov 16, 2022 to Dec 23, 2022
    • Site details revised at 10 of 58 sites
  23. Study sites: 57 to 58v5
  24. Study sites: 56 to 57v4
  25. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Apr 17, 2026 to Dec 24, 2026 · Start date: Oct 15, 2022 to Nov 16, 2022 · Study sites: 0 to 56v3 Show 3 more changesShow less
    • Primary and study completion dates: Apr 17, 2026 to Dec 24, 2026
    • Start date: Oct 15, 2022 to Nov 16, 2022
    • Study sites: 0 to 56
  26. Start date: Aug 24, 2022 to Oct 15, 2022 Primary and study completion dates: Dec 16, 2026 to Apr 17, 2026v2 Show 1 more changeShow less
    • Primary and study completion dates: Dec 16, 2026 to Apr 17, 2026
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
Trial Details
NCT Number NCT05429268
Lead Sponsor Incyte Corporation
Conditions Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov